ArticleThe Lancet regional health. Europe2024

Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial.

Mattia Boeri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.